5 takeaways from 2015 TAVR benchmarks

By Marissa Schwartz, Megan Tooley, and Brian Contos

TAVR has been approved in the U.S. for nearly five years, but excitement over this ever-transforming technology only continues to grow. With positive results from recent trials of intermediate-risk patients, low-risk patient trials underway, and continued emergence of next-generation devices, the TAVR market is poised to keep growing.

To assess how the TAVR market has evolved in recent years, the Cardiovascular Roundtable has updated our benchmarks with the latest Medicare Provider Analysis and Review (MEDPAR) data set for fiscal year (FY) 2015. This includes all Medicare TAVR cases performed between October 1, 2014 and September 31, 2015.

Read on to learn how the TAVR market and practice pattern changes stacked up in FY 2015.

Log in to access this.

Full access to this content is reserved for Cardiovascular Roundtable members.
Log in or learn how membership works.

Next, Check Out

Is the TAVR halo effect real? Our analysis says yes.